| Basics |
Cue Biopharma, Inc.
Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
|
| IPO Date: |
January 2, 2018 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$58.75M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.28 | 3.74%
|
| Avg Daily Range (30 D): |
$0.03 | 3.61%
|
| Avg Daily Range (90 D): |
$0.05 | 4.44%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.23M |
| Avg Daily Volume (30 D): |
.12M |
| Avg Daily Volume (90 D): |
.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
121 |
| Avg Trade Size (Sh.) (30 D): |
334 |
| Avg Trade Size (Sh.) (90 D): |
233 |
| Institutional Trades |
| Total Inst.Trades: |
182 |
| Avg Inst. Trade: |
$2.17M |
| Avg Inst. Trade (30 D): |
$3.81M |
| Avg Inst. Trade (90 D): |
$3.81M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.2M |
| Avg Closing Trade (30 D): |
$3.81M |
| Avg Closing Trade (90 D): |
$3.81M |
| Avg Closing Volume: |
236.3K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.64
|
$-.17
|
$-.1
|
|
Diluted EPS
|
$-.64
|
$-.17
|
$-.1
|
|
Revenue
|
$ 7.99M
|
$ .42M
|
$ 1.58M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -40.58M
|
$ -12.26M
|
$ -9.5M
|
|
Operating Income / Loss
|
$ -41.13M
|
$ -12.3M
|
$ -9.63M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -27.89M
|
$ -9.32M
|
$ -9.96M
|
|
PE Ratio
|
|
|
|
|
